Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 10:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 1,433 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Level B Clear all
Terminated Phase 1Phase 2 Interventional Results available

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma

NCT05255601
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin, Hodgkin Disease
Interventions
Relatlimab, Nivolumab
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
Up to 30 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
13
States / cities
Birmingham, Alabama • Phoenix, Arizona • Palo Alto, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 23, 2026, 10:45 AM EDT
Terminated Phase 1 Interventional

CAR-20/19-T Cells in Patients With Relapsed/Refractory B Cell ALL

NCT04049383
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission, Acute Lymphoblastic Leukemia Recurrent, Acute Lymphoblastic Leukemia Not Having Achieved Remission, Acute Lymphoblastic Leukemia, Pediatric, Acute Lymphoblastic Leukemia
Interventions
CAR-20/19-T cells (5 x 10^5 CAR-20/19-T cells/kg), CAR-20/19-T cells (1 x10^6 CAR-20/19-T cells/kg), CAR-20/19-T cells (2.5 x10^6 CAR-20/19-T cells/kg), CAR-20/19-T cells
Biological
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
1 Year to 70 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Oct 23, 2026, 10:45 AM EDT
Not yet recruiting Phase 4 Interventional

Suzetrigine in Tonsillectomy for Opioid-sparing Pain Management

NCT07821931
View directory record Official record
Conditions
Tonsillectomy, Pharyngoplasty, Suzetrigine, Opioid, Postoperative Pain, Acute Pain
Interventions
Suzetrigine, Acetaminophen, oxycodone
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 23, 2026, 10:45 AM EDT
Completed Phase 1 Interventional

Gene Therapy for Male Patients With Danon Disease (DD) Using RP-A501; AAV9.LAMP2B

NCT03882437
View directory record Official record
Conditions
Danon Disease
Interventions
RP-A501
Biological
Lead sponsor
Rocket Pharmaceuticals Inc.
Industry
Eligibility
8 Years and older · Male only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
3
States / cities
La Jolla, California • Aurora, Colorado • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 23, 2026, 10:45 AM EDT
Completed Phase 1 Interventional

Lenalidomide in Acute Leukemias and Chronic Lymphocytic Leukemia.

NCT00466895
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia
Interventions
lenalidomide
Drug
Lead sponsor
Leslie Andritsos
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 14, 2017 · Synced Oct 23, 2026, 10:45 AM EDT
Completed Not applicable Interventional

TechMPower: Advancing HIV/SUD Care and Service Delivery for People in Re-entry

NCT07088770
View directory record Official record
Conditions
HIV (Human Immunodeficiency Virus), Substance Abuse Disorder
Interventions
Community Coalition CLS Workgroup/Network of Providers, Tech-mediated Training and Service Delivery, Multidisciplinary Implementation Team with Champion, Tech-mediated Peer Navigation Enhanced Case management (NCM)
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Kingston, New York
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Oct 23, 2026, 10:45 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT327) and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer

NCT07079631
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
BNT314, Pumitamig, SoC chemotherapy treatment 1, SoC chemotherapy treatment 2, Bevacizumab
Biological · Drug
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older
Enrollment
482 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
4
States / cities
New Haven, Connecticut • Grand Rapids, Michigan • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 23, 2026, 10:45 AM EDT
Completed Not applicable Interventional

A Randomized, Controlled Trial to Determine the Effects of an Exercise Intervention on Physical Activity During Chemotherapy for Patients With Early Stage Breast Cancer

NCT02159157
View directory record Official record
Conditions
Early Stage Breast Cancer
Interventions
Exercise prescription
Behavioral
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 99 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Aug 21, 2020 · Synced Oct 23, 2026, 10:45 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

First To Know Pregnancy Test - Clinical Evaluation Protocol

NCT07304531
View directory record Official record
Conditions
Pregnancy Detection
Interventions
Diagnostic Test
Device
Lead sponsor
NOWDiagnostics, Inc.
Industry
Eligibility
14 Years and older · Female only
Enrollment
892 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
2
States / cities
Los Angeles, California • Midland, Texas
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 23, 2026, 10:45 AM EDT
Completed Phase 1 Interventional

Intralesional Cemiplimab for Adult Patients With Cutaneous Squamous Cell Carcinoma or Basal Cell Carcinoma

NCT03889912
View directory record Official record
Conditions
Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma
Interventions
Cemiplimab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
9
States / cities
Phoenix, Arizona • San Diego, California • Delray Beach, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Oct 23, 2026, 10:45 AM EDT
Recruiting Not applicable Interventional

Characterization and Clinical Trial of a Variable Friction Shoe

NCT06234124
View directory record Official record
Conditions
Stroke
Interventions
Variable Friction Shoe Training, Ankle Foot Orthosis (AFO) Training
Device
Lead sponsor
Shirley Ryan AbilityLab
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 23, 2026, 10:45 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

A Study to Evaluate Safety and Clinical Activity of GSK5926371 in Adult Participants With Relapsed or Refractory B-NHL

NCT07607925
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin
Interventions
GSK5926371
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Canton, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 23, 2026, 10:45 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

T-regulatory Cell Depletion With E7777 Combined With Pembrolizumab in Recurrent or Metastatic Solid Tumors

NCT05200559
View directory record Official record
Conditions
Epithelial Ovarian Cancer
Interventions
Pembrolizumab, E7777
Drug
Lead sponsor
Alexander B Olawaiye, MD
Other
Eligibility
18 Years and older · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 23, 2026, 10:45 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

PET Scan Imaging of Beta Cell Mass

NCT00771576
View directory record Official record
Conditions
Type 1 Diabetes, Obesity
Interventions
Not listed
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2012
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 18, 2017 · Synced Oct 23, 2026, 10:45 AM EDT
Active, not recruiting Phase 1 Interventional

A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer

NCT04644770
View directory record Official record
Conditions
Prostatic Neoplasms, Adenocarcinoma
Interventions
JNJ-69086420, JNJ-78278343, Stereotactic body radiation therapy
Drug · Radiation
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
11
States / cities
Phoenix, Arizona • Duarte, California • Jacksonville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 23, 2026, 10:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study With Lu AF87908 in Healthy Participants and Participants With Alzheimer's Disease

NCT04149860
View directory record Official record
Conditions
Healthy, Alzheimer Disease
Interventions
Lu AF87908, Placebo
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 65 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
6
States / cities
Glendale, California • Hollywood, Florida • Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2023 · Synced Oct 23, 2026, 10:45 AM EDT
Completed Phase 3 Interventional Results available

Switching Study of Kidney Transplant Patients With Tremor to LCP-Tacro (STRATO)

NCT01438710
View directory record Official record
Conditions
Renal Failure, Tremors
Interventions
Prograf, LCP-Tacro
Drug
Lead sponsor
Veloxis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
10
States / cities
Los Angeles, California • San Diego, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2015 · Synced Oct 23, 2026, 10:45 AM EDT
Completed Phase 1Phase 2 Interventional

Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer

NCT00237627
View directory record Official record
Conditions
Breast Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Ovarian Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
PS-341, Doxil, Velcade
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2010
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 18, 2012 · Synced Oct 23, 2026, 10:45 AM EDT
Completed Phase 1 Interventional

A Study of Atezolizumab Administered in Combination With Bevacizumab and/or With Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors

NCT01633970
View directory record Official record
Conditions
Cancer
Interventions
5-FU, Atezolizumab, Bevacizumab, Carboplatin, Leucovorin, Nab-paclitaxel, Oxaliplatin, Paclitaxel, Pemetrexed
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
11
States / cities
Aurora, Colorado • New Haven, Connecticut • Washington D.C., District of Columbia + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Oct 23, 2026, 10:45 AM EDT
Recruiting Phase 1 Interventional

First-in Cancer-Type Phase I Study of FT536 for Recurrent WHO Grade 4 Astrocytoma

NCT07560865
View directory record Official record
Conditions
Astrocytoma, Glioblastoma, Progressive Disease
Interventions
FT536, Biopsy/ Intratumoral Injection/ Gross Tumor Resection, Blood/ Cerebrospinal Fluid/ Tumor Pathology
Biological · Procedure · Diagnostic Test
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 23, 2026, 10:45 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors

NCT06334432
View directory record Official record
Conditions
Advanced Solid Tumor, HER2-negative Breast Cancer, Metastatic Castration-resistant Prostate Cancer (mCRPC), Pancreatic Cancer, Platinum-resistant Ovarian Cancer (PROC)
Interventions
NUV-1511
Drug
Lead sponsor
Nuvation Bio Inc.
Industry
Eligibility
18 Years and older
Enrollment
466 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
8
States / cities
Detroit, Michigan • Hackensack, New Jersey • New York, New York + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 23, 2026, 10:45 AM EDT
Completed Phase 1 Interventional

Safety and Clinical Pharmacology of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Participants With Advanced Solid Tumors

NCT01362374
View directory record Official record
Conditions
Neoplasms
Interventions
5-FU, Docetaxel, Enzalutamide, Ipatasertib, Leucovorin, Oxaliplatin, Paclitaxel
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
7
States / cities
San Francisco, California • Sarasota, Florida • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2022 · Synced Oct 23, 2026, 10:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Addressing Mental Health in African American Job Training Adolescents and Young Adults

NCT00979524
View directory record Official record
Conditions
Depression
Interventions
Comprehensive Mental Health Services and Supports
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
16 Years to 24 Years
Enrollment
782 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 7, 2016 · Synced Oct 23, 2026, 10:45 AM EDT
Recruiting Phase 2 Interventional

A Phase 2a/b Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Sjögren's Disease

NCT07737743
View directory record Official record
Conditions
Sjögren's Disease
Interventions
DDY391, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
9
States / cities
Clearwater, Florida • Tampa, Florida • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 23, 2026, 10:45 AM EDT